Physician profile
Andre Francois
NPI 1790070837
$1,363.71
in general payments reported to CMS, 2019-2025
15 companies · $296 in 2025
The $296 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $267 · 2020: $60.00 · 2021: $76.72 · 2022: $97.29 · 2023: $181 · 2024: $385 · 2025: $296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $863.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $280.68 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $221.32 | 2019-2022 | |
| Glaxosmithkline, LLC. | $143.43 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Pfizer INC. | $141.95 | 2019-2025 | |
| Abbott Laboratories | $133.63 | 2021-2025 | Freestyle Libre 2 |
| Inspire Medical Systems, INC. | $105.33 | 2024-2025 | Inspire |
| Dexcom, INC. | $83.76 | 2023 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $59.61 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $49.35 | 2024 | Eliquis |
| Novo Nordisk INC | $41.14 | 2025 | Ozempic, Wegovy |
| Merck Sharp & Dohme LLC | $33.86 | 2019 | |
| Boston Scientific Corporation | $27.68 | 2024 | Watchman |
| Sanofi-Aventis U.S. LLC | $16.43 | 2020 | |
| Novartis Pharmaceuticals Corporation | $13.96 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $11.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andre Francois listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.